These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38943034)

  • 1. Safety and effectiveness of oral anticoagulants in patients with atrial fibrillation and stage 4 chronic kidney disease: a real-world experience.
    Talerico R; Brando E; Luzi L; Vedovati MC; Giustozzi M; Verso M; Di Gennaro L; Basso M; Ferretti A; Porfidia A; De Candia E; Pola R; Agnelli G; Becattini C
    Intern Emerg Med; 2024 Sep; 19(6):1645-1652. PubMed ID: 38943034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trials.
    de Lucena LA; Freitas MAA; Souza AKC; Silva CHA; Watanabe JMF; Guedes FL; Almeida JB; de Oliveira RA
    J Thromb Thrombolysis; 2024 Mar; 57(3):381-389. PubMed ID: 38281231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants.
    Trevisan M; Hjemdahl P; Clase CM; de Jong Y; Evans M; Bellocco R; Fu EL; Carrero JJ
    Am J Kidney Dis; 2023 Mar; 81(3):307-317.e1. PubMed ID: 36208798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.
    Loo SY; Coulombe J; Dell'Aniello S; Brophy JM; Suissa S; Renoux C
    BMJ Open; 2018 Jan; 8(1):e019638. PubMed ID: 29371284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.
    Becattini C; Franco L; Beyer-Westendorf J; Masotti L; Nitti C; Vanni S; Manina G; Cattinelli S; Cappelli R; Sbrojavacca R; Pomero F; Marten S; Agnelli G
    Int J Cardiol; 2017 Jan; 227():261-266. PubMed ID: 27843050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
    Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
    Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis.
    Kyriakoulis I; Adamou A; Stamatiou I; Chlorogiannis DD; Kardoutsos I; Koukousaki D; Ntaios G
    Eur J Intern Med; 2024 Jan; 119():45-52. PubMed ID: 37648582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation in Patients with Chronic Kidney Disease.
    Elenjickal EJ; Travlos CK; Marques P; Mavrakanas TA
    Am J Nephrol; 2024; 55(2):146-164. PubMed ID: 38035566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.
    See LC; Lee HF; Chao TF; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; Lip GYH
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):975-986. PubMed ID: 33211254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis.
    Mariani MV; Magnocavallo M; Straito M; Piro A; Severino P; Iannucci G; Chimenti C; Mancone M; Rocca DGD; Forleo GB; Fedele F; Lavalle C
    J Thromb Thrombolysis; 2021 Feb; 51(2):419-429. PubMed ID: 33044735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
    Lorenzoni V; Pirri S; Turchetti G
    Clin Drug Investig; 2021 Mar; 41(3):255-267. PubMed ID: 33587284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent evidence for direct oral anticoagulants in chronic kidney disease.
    Ha JT; Badve SV; Jun M
    Curr Opin Nephrol Hypertens; 2019 May; 28(3):251-261. PubMed ID: 30789840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation.
    Ferroni E; Gennaro N; Costa G; Fedeli U; Denas G; Pengo V; Corti MC
    Int J Cardiol; 2019 Aug; 288():72-75. PubMed ID: 31043323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation.
    Raposeiras-Roubín S; Alonso Rodríguez D; Camacho Freire SJ; Abu-Assi E; Cobas-Paz R; Rodríguez Pascual C; García Comesaña J; González-Carrero López A; Cubelos Fernández N; López-Masjuán Ríos Á; Cespón-Fernández M; Muñoz-Pousa I; Caneiro-Queija B; Rodríguez Albarrán A; Castañera SÁ; Guillén JV; Carpintero Vara A; Barreiro Pardal C; Domínguez-Erquicia P; Domínguez-Rodríguez LM; Díaz Fernández JF; Fernández Vázquez F; Iñíguez-Romo A
    J Am Med Dir Assoc; 2020 Mar; 21(3):367-373.e1. PubMed ID: 31753740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
    Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
    Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study.
    Lee YS; Oh YS; Choi EK; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D
    Open Heart; 2021 Dec; 8(2):. PubMed ID: 34857666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in Japanese patients with ischemic heart disease complicated by atrial fibrillation: A comparative study.
    Nakamura M; Yamashita T; Hayakawa A; Matsumoto T; Takita A; Hasegawa C; Uchino K; Sekine T; Iizuka T; Tanabe H; Kogure S
    J Cardiol; 2021 Feb; 77(2):186-194. PubMed ID: 32943280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study.
    Douros A; Cui Y; Platt RW; Filion KB; Sebastiani G; Renoux C
    Thromb Res; 2024 May; 237():71-78. PubMed ID: 38552497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.